000280917 001__ 280917
000280917 005__ 20250921001953.0
000280917 0247_ $$2doi$$a10.1038/s41531-025-01124-7
000280917 0247_ $$2pmid$$apmid:40883328
000280917 0247_ $$2pmc$$apmc:PMC12397205
000280917 0247_ $$2altmetric$$aaltmetric:180736912
000280917 037__ $$aDZNE-2025-01000
000280917 041__ $$aEnglish
000280917 082__ $$a610
000280917 1001_ $$aBusch, Johannes L$$b0
000280917 245__ $$aChronic adaptive deep brain stimulation for Parkinson's disease: clinical outcomes and programming strategies.
000280917 260__ $$a[London]$$bSpringer Nature$$c2025
000280917 3367_ $$2DRIVER$$aarticle
000280917 3367_ $$2DataCite$$aOutput Types/Journal article
000280917 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1758101471_31854
000280917 3367_ $$2BibTeX$$aARTICLE
000280917 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000280917 3367_ $$00$$2EndNote$$aJournal Article
000280917 520__ $$aAdaptive deep brain stimulation (DBS) dynamically adjusts stimulation amplitude based on neurophysiological feedback and may alleviate residual motor fluctuations in patients with Parkinson's disease. However, potential clinical benefits and programming strategies remain poorly understood. We programmed eight patients with Parkinson's disease on commercially available Dual Threshold adaptive DBS based on subthalamic beta power. Symptom severity was evaluated at home using ecological momentary assessments during two weeks of both continuous and adaptive DBS. Patients were not blinded to the stimulation mode. On the group level, overall well-being significantly improved with adaptive DBS (p = 0.007), and there was a non-significant trend toward enhanced general movement (p = 0.058). Within-subject analysis showed a significant improvement in overall well-being and general movement in three of eight patients. Six of eight patients chose to remain on adaptive DBS. Programming challenges included biomarker selection, threshold definition, and artifact-related maladaptation, for which targeted strategies are reported. Our findings support adaptive DBS as a potential option for selected Parkinson's disease patients with persistent motor symptoms on continuous DBS. We propose a three-step programming approach to guide clinical implementation of adaptive DBS.
000280917 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000280917 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000280917 7001_ $$aKaplan, Jonathan$$b1
000280917 7001_ $$aBehnke, Jennifer K$$b2
000280917 7001_ $$aWitzig, Victoria S$$b3
000280917 7001_ $$aDrescher, Luisa$$b4
000280917 7001_ $$aHabets, Jeroen G V$$b5
000280917 7001_ $$0P:(DE-2719)2811089$$aKühn, Andrea A$$b6$$eLast author$$udzne
000280917 773__ $$0PERI:(DE-600)2819218-7$$a10.1038/s41531-025-01124-7$$gVol. 11, no. 1, p. 264$$n1$$p264$$tnpj Parkinson's Disease$$v11$$x2373-8057$$y2025
000280917 8564_ $$uhttps://pub.dzne.de/record/280917/files/DZNE-2025-01000%20SUP.docx
000280917 8564_ $$uhttps://pub.dzne.de/record/280917/files/DZNE-2025-01000.pdf$$yOpenAccess
000280917 8564_ $$uhttps://pub.dzne.de/record/280917/files/DZNE-2025-01000.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000280917 909CO $$ooai:pub.dzne.de:280917$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000280917 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811089$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000280917 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000280917 9141_ $$y2025
000280917 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000280917 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000280917 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-11
000280917 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000280917 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNPJ PARKINSONS DIS : 2022$$d2024-12-11
000280917 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:43:48Z
000280917 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:43:48Z
000280917 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000280917 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-11
000280917 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000280917 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000280917 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-10T15:43:48Z
000280917 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-11
000280917 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNPJ PARKINSONS DIS : 2022$$d2024-12-11
000280917 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000280917 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000280917 9201_ $$0I:(DE-2719)5000008$$kAG Kühn$$lMovement Disorders (Parkinson's disease, Dystonia)$$x0
000280917 980__ $$ajournal
000280917 980__ $$aVDB
000280917 980__ $$aUNRESTRICTED
000280917 980__ $$aI:(DE-2719)5000008
000280917 9801_ $$aFullTexts